Logotype for Aclaris Therapeutics Inc

Aclaris Therapeutics (ACRS) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Aclaris Therapeutics Inc

Q3 2026 earnings summary

5 Nov, 2026

Executive summary

  • Q3 revenue was $1.481M and net loss was $18.510M; 9M revenue was $5.106M and net loss was $59.839M, with higher R&D expense contributing to wider losses.

  • ATI-052 reported positive Phase 1b results in atopic dermatitis and asthma; bosakitug Phase 2 top-line results and other pipeline milestones are expected in Q4 2026.

  • Cash, cash equivalents and marketable securities totaled $204.607M at quarter-end; October financing generated $46.7M net proceeds.

Financial highlights

  • Q3 revenue was $1.481M vs. $3.299M YoY; 9M revenue was $5.106M vs. $6.531M, primarily reflecting a prior-year Sun Pharma sales milestone.

  • Q3 net loss was $18.510M vs. $14.614M; 9M net loss was $59.839M vs. $45.128M. Operating loss was $21.344M in Q3 and $67.774M for 9M.

  • Q3 R&D expense was $16.066M vs. $13.028M; 9M R&D expense was $49.789M vs. $36.061M, mainly reflecting ATI-052 and ATI-9494 development and manufacturing costs.

  • 9M net cash used in operating activities was $62.076M vs. $33.982M, reflecting higher adjusted net losses and lower cash received from operating assets.

Outlook and guidance

  • Top-line results from the 109-patient Phase 2 ADMIRATION trial of bosakitug in moderate-to-severe atopic dermatitis are expected in Q4 2026.

  • Modzatinib Phase 2b in lichen planus is expected to initiate in Q4 2026; first site activation was expected in November.

  • ATI-9494 IND filing remains on track for Q4 2026.

  • ATI-052 is initially prioritized for a Phase 2b EoE trial planned for early 2027; selection of an additional Phase 2b indication is expected shortly.

  • Following the October offering, available cash and securities are expected to fund operations through H1 2029, excluding potential business development or additional financing.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Aclaris Therapeutics